Cyclerion Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.04
Dividend & YieldN/A$ (N/A)
Beta 1.75
Market capitalization 36.1M
Operating cash flow -42.2M
ESG Scores unknown

Company description

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 979k -250k -1.1M 393k
Total Cashflows From Investing Activities -3.44M -6.71M 18k 1.46M
Net Borrowings 3.51M 3.51M 3.51M
Total Cash From Financing Activities 100.94M 211.57M 28.09M 30.79M
Change To Operating Activities 2.81M -565k -7.84M 988k
Issuance Of Stock 175.51M 175.51M 24.58M 30.79M
Net Income -115.25M -123.01M -77.8M -51.65M
Change In Cash 102.62M 102.62M -44.39M -4.27M
Effect Of Exchange Rate -20k -20k -7k 4k
Total Cash From Operating Activities -97.5M -102.22M -72.49M -36.52M
Depreciation 1.53M 2.7M 2.3M 472k
Change To Account Receivables -1.47M -1.47M 1.35M 27k
Other Cashflows From Financing Activities 100.94M 36.06M
Change To Netincome 12.43M 20.38M 10.61M 13.25M
Capital Expenditures -3.44M -6.89M -1.52M -7k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 7.09M 8.73M 6.8M 3.94M
Income Before Tax -115.25M -123.01M -77.8M -51.65M
Net Income -115.25M -123.01M -77.8M -51.65M
Selling General Administrative 27.54M 34.4M 28.82M 20.62M
Gross Profit -80.62M -81.9M -47.32M -29.75M
Ebit -115.25M -125.04M -82.93M -54.31M
Operating Income -115.25M -125.04M -82.93M -54.31M
Interest Expense
Income Tax Expense
Total Revenue 4.51M 2.3M 3.94M
Cost Of Revenue 80.62M 86.41M 49.62M 33.69M
Total Other Income ExpenseNet -9.01M 2.03M 5.13M 2.67M
Net Income From Continuing Ops -115.25M -123.01M -77.8M -51.65M
Net Income Applicable To Common Shares -115.25M -123.01M -77.8M -51.65M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 17.85M 88.75M 55.88M 11.09M
Total Stockholder Equity -10.45M 97.73M 59.49M 48.25M
Other Current Liabilities 770k 404k 176k 498k
Total Assets 7.4M 186.48M 115.38M 59.33M
Common Stock -10.45M
Other Current Assets 12k 2.86M 1.56M 468k
Retained Earnings -85.63M -163.43M -215.08M
Treasury Stock -20k -27k -23k
Cash 94.89M 54.4M 53.96M
Total Current Liabilities 17.85M 18.25M 16.95M 11.09M
Other Stockholder Equity -20k -27k -23k
Property, Plant, and Equipment 6.5M 79.75M 50.27M 1.47M
Total Current Assets 879k 101.2M 58.5M 55.46M
Net Tangible Assets -10.45M 97.73M 59.49M 48.25M
Net Receivables 1.47M 127k 100k
Accounts Payable 2.78M 3.23M 1.15M 1.83M


Insider Transactions

Here are the insider transactions of stock shares related to Cyclerion Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
HECHT PETER MPurchase at price 3.28 per share.D2021-06-03Chief Executive Officer823.17k
MCGUIRE TERRANCE GPurchase at price 3.12 per share.I2021-06-03Director96.15k
SLATE PATH CAPITAL LPPurchase at price 3.12 per share.I2021-06-03Beneficial Owner of more than 10% of a Class of Security961.54k
HECHT PETER MPurchase at price 2.43 per share.D2021-05-06Chief Executive Officer302k
HECHT PETER MPurchase at price 2.29 - 2.53 per share.D2021-05-05Chief Executive Officer698k
WRIGHT CHRISTOPHER ISale at price 3.99 per share.D2021-02-25Officer2.64k
GJINO ANJEZASale at price 4.00 per share.D2021-02-25Chief Financial Officer1.82k
CURRIE MARK GSale at price 3.01 per share.D2020-12-28President20.11k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Cyclerion Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Cyclerion Therapeutics Inc

Here is the result of two systematic investment strategies applied to Cyclerion Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Cyclerion Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Cyclerion Therapeutics Inc:

Cyclerion Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -31.29% on the backtest period.

Performance at glance

Performance

-31.29 %

Latent gain

-389.47 $

Invested capital

1244.88 $

Annualized return

-11.42 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Cyclerion Therapeutics Inc

This is the result of two momentum investment strategies applied to Cyclerion Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Cyclerion Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Cyclerion Therapeutics Inc:

Cyclerion Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -31.53% of return on Cyclerion Therapeutics Inc. That represents -1261.01$ of latent gain with 3999.43$ of employed capital.
  • The second momentum investment strategy would give -30.9% of return on Cyclerion Therapeutics Inc. That represents -924.99$ of latent gain with 2993.6$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-31.53 %

Latent gain

-1261.01 $

Invested capital

3999.43 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-30.9 %

Latent gain

-924.99 $

Invested capital

2993.6 $

Annualized return

-13.67 %

Momentum equity curve on Cyclerion Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Cyclerion Therapeutics Inc:

Cyclerion Therapeutics Inc momentum equity

Note: the dividends potentially given by Cyclerion Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cyclerion Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Cyclerion Therapeutics Inc since the beginning:

Cyclerion Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Cyclerion Therapeutics Inc

Buy the dip entry openings on Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc

The performance achieved by the robo-advisor on Cyclerion Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Cyclerion Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Cyclerion Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Cyclerion Therapeutics Inc

The following chart shows the result of the investment strategy applied to Cyclerion Therapeutics Inc:

Cyclerion Therapeutics Inc

Note: the dividends potentially given by Cyclerion Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cyclerion Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Cyclerion Therapeutics Inc:

Cyclerion Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Cyclerion Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Cyclerion Therapeutics Inc.

Equity curve comparison on Cyclerion Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Cyclerion Therapeutics Inc investment strategy comparison

Employed capital comparison on Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc investment comparison

Performance comparison on Cyclerion Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -31.29% -389.47$ 1244.88$ -11.42%
Momentum 1 quarter -31.53% -1261.01$ 3999.43$ -12.61%
Momentum 2 quarters -30.9% -924.99$ 2993.6$ -13.67%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-11.42 %

Momentum 1Q

-13.67 %

Momentum 2Q

-13.67 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Cyclerion Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • Cyclerion Therapeutics Inc

  • Most correlated stocks last 3 months

  • Cyclerion Therapeutics Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • CHINA ECO-FARM
  • iShares California Muni Bond ETF
  • Franklin Municipal Green Bond ETF

  • Note: The algorithm computes the probability of correlation between Cyclerion Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Cyclerion Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Cyclerion Therapeutics Inc
    Country United States
    City Cambridge
    Address 245 First Street
    Phone 857 327 8778
    Website www.cyclerion.com
    FullTime employees 32
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker CYCN
    Market www.nasdaq.com

    Cyclerion Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown